 |
인쇄하기
취소
|
Handok denies merger with Teva
Handok Pharm Tuesday denied its merger with Teva Pharmaceutical Industries, the world's leading generic drug manufacturer.
However, Handok officials said the company is still under preliminary negotiation with Teva over the establishment of a joint venture firm, adding further details will be made available within one month.
Currently, Chairman Kim Young-jin is the largest shareholder of ...
However, Handok officials said the company is still under preliminary negotiation with Teva over the establishment of a joint venture firm, adding further details will be made available within one month.
Currently, Chairman Kim Young-jin is the largest shareholder of ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.